InvestorsHub Logo
icon url

Doc328

03/27/23 7:29 AM

#408594 RE: MayoMobile #408588

It's no surprise, there are some good posts and links here. Many companies will also have someone doing competitive intelligence to learn about possibly competing drugs.

There were some posts around 2019 that Dr. Macfarlane reads the MB - My understanding by some is that this means he can not actually be a Dr.
icon url

frrol

03/27/23 8:41 AM

#408600 RE: MayoMobile #408588

There are many basic errors in this "analytics report". As an example, see your entire Clears Lewy Body section. It's just wrong, some nonsensical. There's no benefit to giving an S1 agonist to an S1-knockout mouse; it doesn't have the receptor. The research you cited didn't give "a weak S1 agonist" to the mice. See what those compounds are (one's an antibiotic). You confirmed what you believed, always a mistake in reading research.

I don't know why Anavex would use this, do you?
icon url

jta1980

03/27/23 8:48 AM

#408601 RE: MayoMobile #408588

Very neat. Thanks for
Sharing